Gene Solutions has received US FDA Breakthrough Device Designation for SPOT-MAS 10, its multi-omic blood-based test designed to detect cancer-associated signals.
The designation marks a key regulatory milestone for the Singapore-based biotechnology company as it advances its US development and validation strategy. While Breakthrough Device Designation is not FDA approval, clearance or marketing authorisation, it provides a prioritised pathway for engagement with the agency for qualifying technologies that may offer more effective diagnosis of life-threatening or irreversibly debilitating diseases.
SPOT-MAS 10 is proposed as a qualitative in vitro diagnostic test performed on plasma from a single direct-draw venous whole blood specimen. The test analyses circulating cell-free DNA methylation and fragmentomic signatures using a machine-learning-based algorithm to detect cancer-associated signals.
The test is intended for use as an adjunctive screening tool in asymptomatic adults aged 40 years and above. It is designed to assist in detecting cancers within the assay’s scope, including breast, lung, liver, colorectal, gastric, ovarian, pancreatic, esophageal, endometrial and head and neck cancers.
The platform’s differentiation lies in its multi-omic approach, combining genetics, epigenetics, fragmentomics and AI-driven analysis. Gene Solutions positions SPOT-MAS 10 as a complement to existing guideline-recommended screening programmes, particularly for cancers where established screening pathways remain limited.
The company has generated clinical and real-world evidence to support development of the platform. In March 2025, SPOT-MAS became the first multi-cancer early detection blood test in Asia to complete a large prospective cohort validation. The K-DETEK study, published in BMC Medicine, evaluated SPOT-MAS in more than 9,000 asymptomatic participants and demonstrated high specificity and detection of cancer-associated signals across multiple cancer types.
SPOT-MAS has also been used in more than 100,000 individuals in real-world practice, with data presented at ESMO Asia 2025 and expected to be featured at ASCO Breakthrough 2026 in Singapore. Gene Solutions is targeting US launch readiness in late 2026, supported by its ongoing US laboratory and validation strategy.
As cancer screening moves toward earlier and broader detection models, blood-based multi-cancer tests may play a larger role in expanding access beyond organ-specific screening. Gene Solutions’ next phase will depend on how effectively SPOT-MAS 10 progresses through US regulatory requirements while continuing to build evidence for clinical utility and real-world implementation.
